Abcam PLC - Cambridge, England-based life science research tools - Expects first half revenue to grow 23% to about £185 million.

‘Revenue growth continues to be driven by in-house catalogue sales resulting in gross margin expansion. As the multi-year period of growth investments begins to moderate, we anticipate delivering operating efficiencies enabling year-over-year adjusted operating profit margin expansion consistent with the board’s expectations,’ company says.

For 2022, guides for revenue rise about 20%. In 2021, sees revenue at £315.4 million.

Also notes plans to pursue a sole listing on Nasdaq and cancel its AIM listing in London.

Adds: ‘The company will continue to consult with shareholders on this proposal in the coming weeks with the intention to put the proposal to shareholder approval at a general meeting called for that purpose later this year.’

Current stock price: 1,139.00 pence, up 1.9% in London on Wednesday

12-month change: down 9.6%

Copyright 2022 Alliance News Limited. All Rights Reserved.